Author:
Girardi Enrico, ,Scognamiglio Paola,Angeletti Claudio,Gori Andrea,Buonfrate Dora,Arlotti Massimo,Mazzarello Giovanni,Castagna Antonella,Andreoni Massimo,d'Arminio Monforte Antonella,Antinori Andrea,Ippolito Giuseppe
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C: Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999, 4: 112-21.
2. Guyatt GH, Sackett DL, Cook DJ: Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1993, 270: 2598-2601. 10.1001/jama.1993.03510210084032.
3. Keystone national policy dialogue on expanded access to promising therapeutic drugs for HIV infection and AIDS, with implications for other life-threatening diseases: final report. Keystone, Colo. Keystone Center, 1993. [
http://www.keystone.org/spp/health-and-social-policy/infectious-disease
]
4. Amorosa V, Tebas P: Is It time to rethink the Expanded-Access Programs for HIV infection?. J Infect Dis. 2007, 196: 974-977. 10.1086/521368.
5. EMEA/CHMP, Guideline on compassionate use in the European Community pursuant to Article 83 and the Annex of Regulation (EC) No 726/2004 (July 19, 2007). [
http://www.ema.europa.eu/pdfs/human/euleg/2717006enfin.pdf
]